Latest News

RBL Bank has significantly underperformed the benchmark Nifty bank index over the last 5 years. The stock has lost 67 percent of its value over the last 5 years.

Read More

​ RBL Bank has significantly underperformed the benchmark Nifty bank index over the last 5 years. The stock has lost 67 percent of its value over the last 5 years. RBL Bank has significantly underperformed the benchmark Nifty bank index over the last 5 years. The stock has lost 67 percent of its value over the last 5 years.  Moneycontrol Latest News Read More  

RBL Bank has significantly underperformed the benchmark Nifty bank index over the last 5 years. The stock has lost 67 percent of its value over the last 5 years.

The growth in revenue for EID Parry will be driven by an expansion in the distillery segment.

Read More

​ The growth in revenue for EID Parry will be driven by an expansion in the distillery segment. The growth in revenue for EID Parry will be driven by an expansion in the distillery segment.  Moneycontrol Latest News Read More  

The growth in revenue for EID Parry will be driven by an expansion in the distillery segment.

From its 52-week low of Rs 374, the stock has doubled to Rs 780-level over the past three months

Read More

​ From its 52-week low of Rs 374, the stock has doubled to Rs 780-level over the past three months From its 52-week low of Rs 374, the stock has doubled to Rs 780-level over the past three months  Moneycontrol Latest News Read More  

From its 52-week low of Rs 374, the stock has doubled to Rs 780-level over the past three months

A vacation bench of justices Sudhanshu Dhulia and K V Vishwanathan took note of the submissions for urgent hearing of lawyer Ashwini Updhyay, and said it will not be taking up such pleas during the summer vacation.

Read More

​ A vacation bench of justices Sudhanshu Dhulia and K V Vishwanathan took note of the submissions for urgent hearing of lawyer Ashwini Updhyay, and said it will not be taking up such pleas during the summer vacation. A vacation bench of justices Sudhanshu Dhulia and K V Vishwanathan took note of the submissions for urgent hearing of lawyer Ashwini Updhyay, and said it will not be taking up such pleas during the summer vacation.  Moneycontrol Latest News Read More  

A vacation bench of justices Sudhanshu Dhulia and K V Vishwanathan took note of the submissions for urgent hearing of lawyer Ashwini Updhyay, and said it will not be taking up such pleas during the summer vacation.

The firm reported a 52-percent increase in consolidated net profit at Rs 294 crore for the March quarter, aided by robust sales. Revenue rose to Rs 2,053 crore from Rs 1,726 crore in the year-ago period.

Read More

​ The firm reported a 52-percent increase in consolidated net profit at Rs 294 crore for the March quarter, aided by robust sales. Revenue rose to Rs 2,053 crore from Rs 1,726 crore in the year-ago period. The firm reported a 52-percent increase in consolidated net profit at Rs 294 crore for the March quarter, aided by robust sales. Revenue rose to Rs 2,053 crore from Rs 1,726 crore in the year-ago period.  Moneycontrol Latest News Read More  

The firm reported a 52-percent increase in consolidated net profit at Rs 294 crore for the March quarter, aided by robust sales. Revenue rose to Rs 2,053 crore from Rs 1,726 crore in the year-ago period.

For the fiscal year 2024, Welspun Corp aims to achieve a topline of Rs 15,000 crore, representing a strong growth of around 50 percent. Furthermore, its target for EBIDTA stands at Rs 1,500 crore, growth of around 90 percent. It also aims to significantly improve their ROCE to 16 percent or higher from 7 percent in FY23.

Read More

​ For the fiscal year 2024, Welspun Corp aims to achieve a topline of Rs 15,000 crore, representing a strong growth of around 50 percent. Furthermore, its target for EBIDTA stands at Rs 1,500 crore, growth of around 90 percent. It also aims to significantly improve their ROCE to 16 percent or higher from 7 percent in FY23. For the fiscal year 2024, Welspun Corp aims to achieve a topline of Rs 15,000 crore, representing a strong growth of around 50 percent. Furthermore, its target for EBIDTA stands at Rs 1,500 crore, growth of around 90 percent. It also aims to significantly improve their ROCE to 16 percent or higher from 7 percent in FY23.  Moneycontrol Latest News Read More  

For the fiscal year 2024, Welspun Corp aims to achieve a topline of Rs 15,000 crore, representing a strong growth of around 50 percent. Furthermore, its target for EBIDTA stands at Rs 1,500 crore, growth of around 90 percent. It also aims to significantly improve their ROCE to 16 percent or higher from 7 percent in FY23.

KR Choksey is bullish on Supriya Lifesciences has recommended buy rating on the stock with a target price of Rs 292 in its research report dated May 31, 2023.

Read More

​ KR Choksey is bullish on Supriya Lifesciences has recommended buy rating on the stock with a target price of Rs 292 in its research report dated May 31, 2023. KR Choksey is bullish on Supriya Lifesciences has recommended buy rating on the stock with a target price of Rs 292 in its research report dated May 31, 2023.  Moneycontrol Latest News Read More  

KR Choksey is bullish on Supriya Lifesciences has recommended buy rating on the stock with a target price of Rs 292 in its research report dated May 31, 2023.

Brokerage firm CLSA expects Bharti Airtel#39;s shares to cross Rs 1,000 over the next 12 months.

Read More

​ Brokerage firm CLSA expects Bharti Airtel#39;s shares to cross Rs 1,000 over the next 12 months. Brokerage firm CLSA expects Bharti Airtel#39;s shares to cross Rs 1,000 over the next 12 months.  Moneycontrol Latest News Read More  

Brokerage firm CLSA expects Bharti Airtel#39;s shares to cross Rs 1,000 over the next 12 months.

KR Choksey is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1172 in its research report dated May 31, 2023.

Read More

​ KR Choksey is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1172 in its research report dated May 31, 2023. KR Choksey is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1172 in its research report dated May 31, 2023.  Moneycontrol Latest News Read More  

KR Choksey is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1172 in its research report dated May 31, 2023.

Many first-time employees baulk at investing their first salary because they feel it is too low. All it takes is Rs 500 to start a SIP in a mutual fund.

Read More

​ Many first-time employees baulk at investing their first salary because they feel it is too low. All it takes is Rs 500 to start a SIP in a mutual fund. Many first-time employees baulk at investing their first salary because they feel it is too low. All it takes is Rs 500 to start a SIP in a mutual fund.  Moneycontrol Latest News Read More  

Many first-time employees baulk at investing their first salary because they feel it is too low. All it takes is Rs 500 to start a SIP in a mutual fund.